The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome.
Recent research into the Guillain-Barré syndromes (GBS) has focused on anti-ganglioside antibodies that correlate with specific clinical phenotypes. Our increasing understanding of the role of antibodies in mediating GBS has naturally focused our attention on complement involvement in the pathological procession. We have studied the axonal and glial components of the murine motor nerve terminal as a model site of antibody and complement mediated injury. Such studies are providing us with clear information on the molecular components underlying our clinicopathological model for GBS and have lead us to the testing of emerging complement therapeutics that are potentially suitable for human use.
Willison
Hugh J
HJ
Division of Clinical Neurosciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK. h.j.willison@clinmed.gla.ac.uk
Halstead
Susan K
SK
Beveridge
Erin
E
Zitman
Femke M P
FM
Greenshields
Kay N
KN
Morgan
B Paul
BP
Plomp
Jaap J
JJ
D000818:Animals; D000906:Antibodies / Q000378:metabolism; D003165:Complement System Proteins / Q000502:physiology*; D004195:Disease Models, Animal; D005732:Gangliosides / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000502:physiology*; D051379:Mice; D008954:Models, Biological; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*
D000906:Antibodies; D005732:Gangliosides; D007155:Immunologic Factors; D003165:Complement System Proteins